GSK Combined Melanoma Treatment Delayed in Europe

GlaxoSmithKline (GSK), the UK's largest pharmaceutical company, has provisionally withdrawn its marketing authorization application to the European Medicines Agency (EMA) for the combined use of Tafinlar (also known as dabrafenib, Mekinist, or trametinib).

Unlike its U.S. counterpart, Food and Drug Administration (FDA), the European  agency declined to grant accelerated approval of the combined melanoma treatment based on limited data from ongoing Phase III clinical trials.

The company said it would resubmit the application when it has more data.

Tafinlar is already approved in Europe, while Mekinist is still being reviewed. GSK believes the two drugs will have a longer-lasting effect if given together, and industry analysts see a combination offering the greatest commercial potential.

Like Roche's rival medicine Zelboraf, GSK's Tafinlar is a BRAF inhibitor, designed to work in patients with a mutation of a gene known as BRAF. While such drugs have been effective in shrinking melanoma tumors but most patients eventually develop resistance to the drugs, reports said.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.